Investor Presentation

Date: 06th November, 2026 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Mumbai - 400001 Bandra-Kurla Complex, BSE Symbol: ANUHPHR Bandra (E), Mumbai – 400051 BSE Scrip Code: 506260 NSE Symbol: ANUHPHR; Series: EQ Sub: Investor Presentation – Q2 and H1 FY 2026-27. Dear Sir/Madam, With reference to the subject mentioned above and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Investor Presentation for Q2 and H1 FY 2026-27. This intimation is also being uploaded on the Company's website at www.anuhpharma.com. Kindly take the above on your records. Thanking you, Yours faithfully, FOR ANUH PHARMA LIMITED MANAN VADHAN COMPANY SECRETARY & COMPLIANCE OFFICER Encl: As above ANUH PHARMA LTD. Investor Presentation H1 FY27 | November 2026 BSE - 506260, NSE- ANUHPHR Bloomberg: ANUH IN | Reuters: ANUH.BO www.anuhpharma.com Safe Harbour Statement ▪ This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. ▪ Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements. ▪ The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. ▪ No part of this presentation may be reproduced, quoted or circulated without prior written approval from Anuh Pharma Limited. Anuh Pharma Limited | Investor Presentation H1 FY27 H1 FY27 & H1 FY 26 Performance Company Overview Table of Contents Infrastructure Future Outlook Corporate Social Responsibility H1 FY27 & H1 FY26 Performance H1 FY27 & H1 FY 26 at a Glance Rs. in Crores Operating Revenue Operating Profit EBITDA Profit Before Tax 379.05 78.11 36.92 31.98 +1.80% YoY +26.23% YoY +39.11% YoY +53.19% YoY Rs. 372.36 Cr in H1 FY26 20.61% margin vs 16.62% LY 9.74% margin vs 7.13% LY 8.44% margin vs 5.60% LY PAT ROCE EPS (Rs.) Production (MT) 22.64 16.52% 2.26 987 MT +42.25% YoY +60 bps vs FY26 +42.06% YoY +15.31% YoY 5.97% margin vs 4.27% LY FY26: 15.92% H1 FY26: Rs. 1.59 H1 FY26: 856 MT Message from the Joint Managing Directors – H1 FY27 H1 FY27 – PROFITABILITY Dear Shareholders, Investors and Partners, 379.05 Revenue (Cr) +1.80% In H1 FY27 we chose margin over volume. Revenue was broadly flat at Rs. 379 Cr, while PAT rose 42% and EBITDA margin improved by 261 bps to 9.7%. 36.92 EBITDA (Cr) +39.11% Higher-value products replaced lower-margin volumes, and domestic demand offset softer exports. 22.64 PAT (Cr) +42.25% Production grew 15%, and ROCE reached 16.5%. With our new Tarapur unit commissioned, capacity of 2,975 MTPA our H2 priority is to rebuild exports and H1 FY27 – OPERATIONS & RETURNS deliver 15–20% annual growth. Production (MT) +15.31% We thank you for your continued trust and support. 31.98 PBT (Cr) +53.19% Ritesh Shah, Joint MD | Vivek Shah, Joint MD 16.52% ROCE +60 bps H1 FY27 Financial Performance Rs. in Crores Financial Highlights Q2 FY27 Q1 FY27 % QoQ H1 FY27 H1 FY26 % YoY Operating Revenue 185.24 193.81 (4.42) 379.05 372.36 1.80 Operating Profit * 39.96 38.15 4.75 78.11 61.87 26.23 % of Margin 21.57 19.68 20.61 16.62 Other Income 0.61 3.08 (80.23) 3.69 4.37 (15.61) EBITDA 17.55 19.36 (9.36) 36.92 26.54 39.11 % of Margin 9.47 9.99 9.74 7.13 Interest 0.05 0.00 1,381.29 0.06 0.29 (80.71) Depreciation 2.45 2.43 0.78 4.88 5.38 (9.15) PBT 15.05 16.93 (11.11) 31.98 20.87 53.19 TAX 3.83 5.50 (30.32) 9.34 4.96 88.26 PAT 11.21 11.42 (1.85) 22.64 15.91 42.25 Reported EPS (Rs.) 1.12 1.14 (1.86) 2.26 1.59 42.06 * Operating Profit = PBT + Depreciation + Other Expenses - Other Income. Figures in brackets denote decline. Five-Year Financial Track Record Rs. in Crores | FY22 - FY26 Total Revenue EBITDA 87.2 776.0 70.4 659.0 671.0 66.1 57.4 491.8 537.0 52.0 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Profit Before Tax and Profit After Tax PBT PAT 78.3 60.1 61.0 54.2 47.5 47.4 47.4 39.1 36.2 30.6 FY22 FY23 FY24 FY25 FY26 Balance Sheet Strength & Shareholder Returns FY22 - FY26 Dividend Outflow (Rs. Cr.) Current Ratio (x) 2.22 2.20 15.03 15.03 2.11 12.53 10.02 8.77 1.98 1.91 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Debt to Equity (x) Cash Conversion Cycle (Days) 0.03 86 58 56 61 0.01 0.01 0.00 0.00 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 # FY26 dividend as proposed. Revenue Mix & Customer Concentration H1 FY27 vs H1 FY26 Domestic vs Export Revenue (Rs. Cr.) Top 5 Customers - Share of Sales Domestic Export H1 FY27 H1 FY26 135 46% H1 FY27 H1 FY26 Export Domestic Total Export Revenue by Geography % of export sales H1 FY27 H1 FY26 2.5% 3.5% 24.4% 30.3% 32.7% 41.9% 4.1% 3.7% 27.1% 29.7% Asia Europe North America Asia Europe North America Africa Latin America Africa Latin America Product Mix - H1 FY27 vs H1 FY26 Rs. in Crores Revenue by Product Group H1 FY27 H1 FY26 107.0 Erythromycin 119.3 77.7 Sulphadoxine 33.1 64.7 Higher Macrolides 50.4 41.5 Cortico Steroids 43.4 24.1 Gliclazide 17.9 Pyrazinamide 20.4 12.8 Ambroxol HCL 13.6 10.9 Chloramphenicol 20.1 21.1 Other Items 60.9 Company Overview Anuh Pharma at a Glance API manufacturer since 1989 ~46% 360 72+ 3 of FY26 revenue from marketing partners / countries served facilities - 2 at Tarapur, 1 at exports customers Mahape Business Profile Infrastructure & Group ▪ One of the largest manufacturers of Macrolides and ▪ Two manufacturing facilities at Tarapur; the new facility Anti-TB products in India. is spread over 9,520 sq. mtrs of land. ▪ Major player in Anti-bacterials, Anti-malarial, Anti- ▪ R&D facility at Mahape spread over 10,000 sq. ft. hypertension and Corticosteroids. ▪ Part of the INR 8.5 bn SK Group, employing ~2,200 ▪ Strong marketing partnerships with 360 customers in people across pharma formulations, trading, distribution over 72 countries, including Europe, Mexico and South and logistics. Africa. ▪ The Company derived ~46% of its revenues from exports in FY26. Journey So Far 1989 - 2026 FOUNDATION 1989 - 2010 GLOBAL APPROVALS 2012 - 2019 SCALE & GROWTH 2020 - 2026 1989 Started manufacturing 2012 Acquired R&D assets of Invent 2020 WHO Geneva pre-qualification Erythromycin salts with capacity of 150 Pharma (Spain); DSIR approval. for Pyrimethamine API. MTPA. 2014 COFEPRIS Mexico approval for 2023 CEP from EDQM for 1995 Doubled the capacity to 300 three Erythromycin salts. Sulphadoxine, Azithromycin & MTPA. Gliclazide; capacity to 1,800 MTPA. 2015 COFEPRIS Mexico for 2024 WHO pre-qualification for 2002 Received WHO-GMP for its Chloramphenicol & Palmitate; WHO Isoniazid plus renewals; CEP for facilities. pre-qualification for Sulphadoxine. Allopurinol & Ambroxol HCL. 2006 New plot of 1,800 SQMT; output 2017 DMF approval from UK MHRA 2024 Capacity 1,800 to 2,200 MTPA; capacity expanded to 600 MTPA. for Erythromycin Stearate. got listed on NSE. 2010 COS and EU/GMP approval for 2018 Certificate of GMP (WHO GMP) 2025 Capacity 2,200 to 2,400 MTPA; Erythromycin, Erythromycin Ethyl from FDA Maharashtra. CEP from EDQM for Sulfadimethoxine. Succinate and Pyrazinamide. 2019 WHO pre-qualification for 2026 USFDA inspection completed Pyrazinamide & Sulphadoxine; EU successfully with zero 483 GMP from AEMPS Spain. observations. 2019 New 7,800 SQMT plot (+600 2026 WHO pre-qualification for MTPA); USFDA inspection passed, zero Amodiaquine HCL; awarded EcoVadis 483 observations. Bronze Medal. 2026 New 9,520 SQMT facility at Tarapur; 3 facilities in total. Competitive Advantage Market Leadership Why Customers Choose Anuh Products where Anuh holds a leading position Regulatory approvals Erythromycin salts USFDA, EU GMP, WHO-GMP, EDQM CEPs and WHO Geneva pre- qualifications across the portfolio. Environmental, health and safety [Showing first 8,000 characters — download PDF for full document]